Treatment of hypercholesterolaemia in patients with primary biliary cirrhosis may be more beneficial than indicated

Swiss Medical Weekly

Volumn 138, Issue 29-30, 2008, Pages 415-419

  Bahner, Maria Luisa ^a   Dufour, Jean François ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cardiovascular risk factors; Cholestasis; Cholesterol; Fibrate; Primary biliary cirrhosis; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ATORVASTATIN; BEZAFIBRATE; BILIRUBIN; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN M; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; URSODEOXYCHOLIC ACID; VERY LOW DENSITY LIPOPROTEIN; CLOFIBRIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG WITHDRAWAL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; PRIMARY BILIARY CIRRHOSIS; SHORT SURVEY; SIDE EFFECT; TREATMENT RESPONSE; BILIARY CIRRHOSIS; CARDIOVASCULAR DISEASE; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER CIRRHOSIS, BILIARY; RISK FACTORS; URSODEOXYCHOLIC ACID;

EID: 48349115722     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (25)

1. Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology. 1992;15:858-62.
2. Poupon RE, Ouguerram K, Chretien Y, Verneau C, Eschwege E, Magot T, et al. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology. 1993;17:577-82.
3. Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, et al. Hypercholesterolemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. 2006;55:1795-800.
4. Ahrens EH Jr, Kunkel HG. The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis. J Clin Invest. 1949;28:1565-74.
5. Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265-9.
6. Su TC, Hwang JJ, Kao JH. Hypercholesterolemia in primary biliary cirrhosis. N Engl J Med. 2007;357:1561-2.
7. Balan V, Dickson ER, Jorgensen RA, Lindor KD. Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin Proc. 1994;69:923-9.
8. Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezanbrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol. 2000;95:2990-2.
9. Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000;95:326-7.
10. Chianale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J. 1996;314(Pt 3):781-6.
11. Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol. 2002;36:454-8.
12. Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2007;46:776-84.
13. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287-92.
14. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006;4:902-7; quiz 806.
15. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-402.
16. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-92.
17. Yokomori H, Oda M, Yoshimura K, Nomura M, Ogi M, Wakabayashi G, et al. Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 protein and messenger RNA in primary biliary cirrhosis. Intern Med. 2003;42:947-54.
18. Yokomori H, Oda M, Ogi M, Wakabayashi G, Kawachi S, Yoshimura K, et al. Expression of adhesion molecules on mature cholangiocytes in canal of Hering and bile ductules in wedge biopsy samples of primary biliary cirrhosis. World J Gastroenterol. 2005;11:4382-9.
19. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-8.
20. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
21. Carrella M, Feldman D, Cogoi S, Csillaghy A, Weinhold PA. Enhancement of mdr2 gene transcription mediates the biliary transfer of phosphatidylcholine supplied by an increased biosynthesis in the pravastatin-treated rat. Hepatology. 1999;29:1825-32.
22. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet. 2000;355:2218-9.
23. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000;355:2185-8.
24. Jeanpierre E, Le Tourneau T, Zawadzki C, Van Belle E, Mouquet F, Susen S, Ezekowitz MD, Staels B, Jude B, Corseaux D. Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits. Cardiovasc Pathol. 2008 Apr 22.
25. Wagner M, Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rational approach to the treatment of intrahepatic cholestasis. Ann Hepatol. 2005;4(2):77-99.